success rate of compounded semaglutide vs. Tirzepatide: Which GLP-1 for You | Harbor Over 80% of semaglutide users

As of early 2025, retatrutide remains an investigational medication that has not yet received approval from the MHRA (Medicines and Healthcare products Regulatory Agency) or other major regulatory bodies

4 Placebo-adjusted weight reduction is even greater for patients without diabetes: 12.4% for semaglutide and 17.8% for tirzepatide

Dosing regimens for both products involve gradual titration to optimize therapeutic outcomes

Microdosing is an alternative that involves taking a prescribed low dose

Recent phase 2 trials show unprecedented weight loss, improved glycemic control, favorable changes in fat mass and liver fat, and a promising safety profile

WHAT'S INSIDE?- GLP-1 Probiotic is formulated with the beneficial bacterial strains that help you produce more GLP-1, based on preclinical studies